Industrial news
The global process analytical technology market has been projected to expand steadily through to at least 2031, driven by regulatory pressure, the transition to continuous manufacturing and increasing investment in artificial intelligence-enabled process monitoring across pharmaceuticals and advanced manufacturing
The global market for process analytical technology has been projected to expand from $4.81 billion in 2025 to $6.88 billion by 2031, reflecting a compound annual growth rate of 6.15 per cent over the forecast period, according to a report by ResearchAndMarkets.com. This growth trajectory has been attributed to structural changes in manufacturing, particularly the shift away from batch production towards continuous processes, alongside rising regulatory expectations for real-time quality assurance and tighter process control.
Process analytical technology – commonly referred to as PAT – has been defined as a systematic framework to design, analyse and control manufacturing processes through timely measurement of critical quality and performance attributes. Its adoption has become increasingly central to modern manufacturing strategies, particularly within regulated industries, where Quality by Design principles have been embedded within both regulatory guidance and operational best practice. Manufacturers have sought to improve yields, reduce waste, and minimise the risk of batch failure – all of which have reinforced demand for integrated analytical monitoring systems.
The transition from batch to continuous manufacturing has been a particularly strong catalyst. Continuous processes require uninterrupted visibility of process conditions, which has compelled manufacturers to deploy in-line and at-line analytical tools capable of operating in real time. This trend has been reinforced by broader digitalisation efforts across industry. According to the US National Association of Manufacturers, 28 per cent of surveyed manufacturers in 2024 reported active implementation of digitalisation and technology transformation projects, underlining the scale of change underway across production environments.
Despite this momentum, the market has continued to face notable structural barriers. The integration of PAT platforms within existing legacy infrastructure has often required substantial upfront capital expenditure on specialised instrumentation, advanced software and supporting digital architecture. In parallel, organisations have required highly trained personnel to interpret complex multivariate and chemometric data, which has further increased implementation costs. These factors have tended to deter smaller and mid-sized enterprises, particularly in cost-sensitive sectors, from pursuing comprehensive analytical deployments, thereby slowing overall market penetration.
The incorporation of artificial intelligence (AI) and the ‘Industrial Internet of Things’ has emerged as a major driver of recent market progress. These technologies have supported a shift away from reactive quality control towards predictive, real-time process assurance, allowing manufacturers to identify deviations before they compromise product quality.
Evidence of this transition has been reflected in industry surveys. As reported in Rockwell Automation’s 9th Annual State of Smart Manufacturing Report published in March 2024, 83 per cent of manufacturers anticipated the use of generative AI within their operations during that year, signalling growing widespread intent to modernise analytical and control infrastructure.
Labour market pressures have further accelerated this trend. Workforce shortages have increased reliance on automated systems to maintain production continuity and compliance. According to ManpowerGroup’s 2024 Global Talent Shortage report, published in January 2024, 75 per cent of employers globally reported difficulty in recruiting suitably skilled staff, reinforcing the case for automated and intelligent analytical solutions within manufacturing environments.
At the same time, rising research and development investment within biopharmaceutical and biosimilar manufacturing has increased demand for advanced process analytical technologies. As production pipelines have shifted towards complex biologics, tolerance for process variability has narrowed considerably. Continuous and highly sensitive monitoring has become essential to maintain regulatory compliance, ensure batch consistency, and protect high-value products. This strategic priority has been reflected in major capital investment announcements. In June 2024, Novo Nordisk announced an investment of $4.1 billion to construct a second fill-and-finish facility in Clayton, North Carolina, highlighting the central role of advanced process control in securing returns on large-scale manufacturing assets.
Nevertheless, financial pressures across industrial sectors have continued to constrain investment decisions. The substantial capital outlay required to implement PAT solutions has coincided with a period of rising operating costs. According to Make UK, 70 per cent of manufacturers reported in 2024 that operating costs had increased by up to 20 per cent compared with the previous year. In such conditions, many organisations have prioritised short-term operational stability over long-term digital transformation, which has directly limited the pace of PAT adoption.
Alongside these challenges, technological innovation within the market has continued. The adoption of digital twin technology for real-time process simulation has enabled manufacturers to create virtual replicas of production lines, allowing them to test parameters and forecast outcomes within a risk-free digital environment. This approach has reduced both the time and cost associated with physical experimentation and has been particularly prominent within life sciences manufacturing, where speed to market remains critical. According to Rockwell Automation’s State of Smart Manufacturing Report: Life Sciences Edition, published in August 2024, life sciences manufacturers identified generative design and simulation as their leading investment priority, underlining the growing importance of AI-driven process modelling.
In parallel, advances in multiparameter and hybrid spectroscopic analysis have expanded the scope of critical quality attribute monitoring. Manufacturers have increasingly adopted machine vision and advanced optical systems capable of simultaneous assessment of multiple physical and chemical properties. This shift has moved quality assurance beyond single-point sensing towards comprehensive spatial inspection, enabling automated visual analysis that has reduced dependence on manual inspection and mitigated human error. Support for this direction has been reflected in industry surveys. According to Zebra Technologies’ 2024 Manufacturing Vision Study, published in June 2024, 66 per cent of manufacturers globally reported plans to deploy machine vision systems within the next five years to strengthen quality management capabilities.
Major suppliers operating within the process analytical technology market have included Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation, Bruker Corporation, PerkinElmer, ABB, Carl Zeiss, Emerson Electric, Mettler-Toledo, Shimadzu Corporation, Sartorius, and Hamilton Company. Together, these organisations have continued to invest in integrated analytical platforms that combine spectroscopy, chromatography, machine vision, and advanced data analytics to meet evolving regulatory and operational demands.
Overall, the process analytical technology market has been shaped by a complex interplay of regulatory pressure, technological innovation, and economic constraint. While high entry barriers and financial pressures have moderated adoption in some segments, sustained investment in digital manufacturing, biopharmaceutical production, and AI-enabled analytics has underpinned a positive long-term outlook for the sector.
For further reading please click here
Product directory
